ストックスクリーナーアプリを入手
14.05
0.04%
0.005
アフターアワーズ：
14.05
前日終値:
$14.04
開ける：
$13.9967
24時間の取引高:
2,393
Relative Volume:
0.08
時価総額：
$36.70M
収益：
$5.02M
当期純損益:
$-18.31M
株価収益率:
-3.1015
EPS:
-4.53
ネットキャッシュフロー:
$-23.40M
1週間 パフォーマンス:
+1.81%
1か月 パフォーマンス:
-9.18%
6か月 パフォーマンス:
-36.45%
1年 パフォーマンス:
+62.11%
1日の値動き範囲:
$14.00
$14.05
1週間の範囲:
$13.20
$14.35
52週間の値動き範囲:
$7.38
$30.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
VTVT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
14.05 | 36.70M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-05-30 | 開始されました | H.C. Wainwright | Buy |
| 2018-04-10 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-08 | 開始されました | ROTH Capital | Buy |
| 2018-02-08 | 開始されました | Northland Capital | Outperform |
| 2016-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2015-09-04 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-24 | 開始されました | Piper Jaffray | Overweight |
| 2015-08-24 | 開始されました | Stifel | Buy |
すべてを表示
Vtv Therapeutics Inc (VTVT) 最新ニュース
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
vTv Therapeutics Highlights Progress on Diabetes Treatment - TipRanks
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
(VTVT) Investment Analysis - Stock Traders Daily
Trend Tracker for (VTVT) - Stock Traders Daily
Where are the Opportunities in (VTVT) - Stock Traders Daily
Fmr LLC Takes $2.40 Million Position in vTv Therapeutics Inc. (NASDAQ:VTVT) - Defense World
vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Update - Defense World
Vimeo, Inc. (NASDAQ:VMEO) Sees Significant Increase in Short Interest - Defense World
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at Alliance Global Partners - Defense World
Alliance Global Partners Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - MSN
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - The Malaysian Reserve
Cantex Scores Third FDA Orphan Drug Win for Breakthrough Breast Cancer Brain Metastasis Treatment - StockTitan
(VTVT) Long Term Investment Analysis - Stock Traders Daily
vTv Therapeutics (FRA:5VT0) EBITDA : €-20.38 Mil (TTM As of Sep. 2024) - GuruFocus.com
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - The Manila Times
vTv Therapeutics to Present at Evercore HealthCONx Conference in December 2024 - StockTitan
vTv Therapeutics (STU:5VT0) Shares Outstanding (EOP) : 2.61 Mil (As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Operating Cash Flow per Share : €-4.95 (TTM As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Change In Receivables : €-0.12 Mil (TTM As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Cash Flow from Financing : €48.09 Mil (TTM As of Sep. 2024) - GuruFocus.com
VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors - GlobeNewswire
Insider Buying: Paul Sekhri Acquires Shares of vTv Therapeutics Inc (VTVT) - GuruFocus.com
vTv therapeutics CEO Paul Sekhri buys $83,811 in stock - Investing.com
vTv Therapeutics (NASDAQ:VTVT) shareholders are up 29% this past week, but still in the red over the last five years - Simply Wall St
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71% - Yahoo Finance
Objective long/short (VTVT) Report - Stock Traders Daily
vTv Therapeutics (FRA:5VT0) 5-Year EBITDA Growth Rate : 25.50% (As of Jun. 2024) - GuruFocus.com
VTv Therapeutics: Q3 Earnings Snapshot - Darien Times
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance - The Manila Times
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update - GlobeNewswire
vTv Therapeutics Faces License Agreement Termination - Yahoo Finance
How the (VTVT) price action is used to our Advantage - Stock Traders Daily
VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch
vTv Therapeutics ends key license agreement with OnKure - Investing.com
VTv Therapeutics : Termination of Material Agreement Form 8 K - Marketscreener.com
VTv Therapeutics: Q2 Earnings Snapshot - Barchart
Alzheimer's disease Market Size in the 7MM was ~USD 3,500 Million in 2022 | DelveInsight - openPR
Trading (VTVT) With Integrated Risk Controls - Stock Traders Daily
Resolution names Paul Sekhri chair - BioCentury
Alzheimer’s disease Treatment Market Size in the 7MM was ~USD 3,500 Million in 2022, estimated DelveInsight - Barchart
Alzheimer’s Disease Treatment Market Trends As Discussed In New Market Research Report - WhaTech
Vtv Therapeutics Inc (VTVT) 財務データ
収益
当期純利益
現金流量
EPS
Vtv Therapeutics Inc (VTVT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SEKHRI PAUL J | Pres, CEO and Exec Chairperson |
Nov 18 '24 |
Buy |
16.96 |
1,844 |
31,269 |
5,000 |
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):